Inspire Medical Systems, Inc. (INSP) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Hold
Based on 27 analysts11.8% Below Target
INSP trades 11.8% below Wall Street's consensus target of $56.00.
Current Price$50.08
Average Target$56.00
Target
Current
Low$39.00
Median$55.00
High$70.00
Analyst Target Range
Forward P/E55.9x
(High Premium)
PEG Ratio—
Implied Growth-80.4%
(Declining)
Analyst Spread55.4%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes INSP achieves its forward estimates and maintains a stable P/E multiple of 55.9x. This scenario reflects the blended consensus of 27 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
INSP Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Inspire Medical Systems, Inc. (INSP) has a Wall Street consensus price target of $56.00, based on estimates from 27 covering analysts. With the stock currently trading at $50.08, this represents a potential upside of +11.8%. The company has a market capitalization of $1.44B.
Analyst price targets range from a low of $39.00 to a high of $70.00, representing a 55% spread in expectations. The median target of $55.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 10 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, INSP trades at a trailing P/E of 10.2x and forward P/E of 55.9x. Analysts expect EPS to grow -80.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $21.67, with bear and bull scenarios of $13.65 and $28.55 respectively. Model confidence stands at 67/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+46.7%
Industry Consensus
Avg Forward P/E
23.1x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
 TNDMTandem Diabetes Care, Inc. | $1.1B | $15.43 | $29.95 | +94.1% | Buy | — | 39 |
 IRTCiRhythm Technologies, Inc. | $4.1B | $125.09 | $188.75 | +50.9% | Buy | — | 20 |
 MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
 ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
 BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
 LVSLas Vegas Sands Corp. | $30.6B | $46.06 | $67.89 | +47.4% | Buy | 13.9x | 49 |
 RGENRepligen Corporation | $7.9B | $139.83 | $158.67 | +13.5% | Buy | 69.8x | 24 |
 MMSIMerit Medical Systems, Inc. | $4.3B | $72.14 | $94.20 | +30.6% | Buy | 17.7x | 14 |
 ITGRInteger Holdings Corporation | $3.2B | $91.90 | $108.00 | +17.5% | Buy | 15.1x | 15 |
INSP — Frequently Asked Questions
Quick answers to the most common questions about buying INSP stock.
What is the INSP stock price target for 2026?
Inspire Medical Systems, Inc. (INSP) has a consensus 12-month price target of $56, implying 11.8% upside from $50.08. The 27 analysts covering INSP see moderate appreciation potential.
Is INSP a buy, sell, or hold?
INSP has a consensus rating of "Hold" based on 27 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $56 implies 11.8% upside from current levels.
Is INSP stock overvalued or undervalued?
At a forward P/E of 55.9116x, INSP trades at a premium valuation. The consensus price target of $56 (11.8% upside) suggests analysts still see growth justifying the multiple.
How high can INSP stock go?
The most bullish Wall Street analyst has a price target of $70 for INSP, while the most conservative target is $39. The consensus of $56 represents the median expectation. Our quantitative valuation model projects a bull case target of $29 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover INSP stock?
INSP is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 17 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the INSP stock forecast?
The 12-month INSP stock forecast based on 27 Wall Street analysts shows a consensus price target of $56, with estimates ranging from $39 (bear case) to $70 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $22, with bear/bull scenarios of $14/$29.
What is INSP's fair value based on fundamentals?
Our quantitative valuation model calculates INSP's fair value at $22 (base case), with a bear case of $14 and bull case of $29. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 67/100.
What is INSP's forward P/E ratio?
INSP trades at a forward P/E ratio of 55.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 10.2x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy INSP stock?
Wall Street analysts are optimistic on INSP, with a "Hold" consensus rating and $56 price target (11.8% upside). 10 of 27 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do INSP price targets vary so much?
INSP analyst price targets range from $39 to $70, a 55% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $56 consensus represents the middle ground. Our model's $14-$29 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare